Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with metastatic castration-resistant prostate cancer with a deleterious germline or somatic BRCA mutation confirmed by an FDA-approved companion diagnostic, after androgen receptor-directed therapy.
LAMPGEN ANALYSIS
Why it matters
TRITON3 confirmed benefit in BRCA-mutated disease and the traditional label removed the prior taxane requirement from the 2020 accelerated indication.
What research teams should watch
Capture the BRCA companion diagnostic and previous androgen receptor-directed treatment without assuming a prior taxane is required.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Metastatic castration-resistant prostate cancerPRIMARY RECORDS